Drug Interactions With Risk of QT-prolongation in a General Hospital

Catholic University (KU) of Leuven

Status: Completed

Conditions: QT-prolongation

Treatments: Drug: Haloperidol

Study type: Observational

Funder types: Other

Identifiers

NCT02043912

EV002

Details and patient eligibility

About

In this epidemiological point prevalence study, medication profiles of patients with haloperidol treatment will be checked for drug interactions with risk of QT-prolongation. Additional clinical risk factors for developing QT-prolongation and safety measurements will be documented.

Full description

Study design: epidemiological point prevalence study

Target population: Patients with haloperidol treatment

The following aspects will be investigated:

• The medication profiles will be checked for drug interactions with risk of QT-prolongation.
• Clinical risk factors for developing QT-prolongation (gender, age, (history of) cardiovascular disease, comorbidity,...) and lab results will be collected.
• Safety measurements (e.g. ECG) will be documented.

Enrollment: 222 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• treatment with haloperidol (started in the hospital)

Exclusion criteria

• age < 18 years

Trial design

222 participants in 1 patient group

patients treated with haloperidol

Treatment:

Drug: Haloperidol